10-KPeriod: FY2014

AMGEN INC Annual Report, Year Ended Dec 31, 2014

Filed February 19, 2015For Securities:AMGN

Summary

Amgen Inc. reported strong financial performance for the fiscal year ended December 31, 2014, with total revenues reaching $20.06 billion, a 7% increase year-over-year. This growth was primarily driven by robust product sales, particularly in international markets, and the inclusion of Kyprolis® sales following the Onyx acquisition. The company demonstrated a commitment to returning capital to shareholders through increased dividends and ongoing stock repurchase programs. Significant pipeline advancements were made in 2014, with several key product candidates progressing through late-stage clinical trials and regulatory submissions. Notably, Repatha™ (evolocumab) for high cholesterol and BLINCYTO™ for acute lymphoblastic leukemia showed promising developments, with BLINCYTO™ receiving FDA accelerated approval in December 2014. Amgen is also strategically investing in next-generation biomanufacturing and has initiated a restructuring plan to optimize its cost structure and reallocate resources towards innovation and new product launches. However, the company faces increasing competition from biosimilars and anticipates patent expirations for key products, which will require continued focus on R&D and strategic pipeline management.

Financial Highlights

55 data points
Beta

Revenue

$20.06B

78.0% Gross Margin

Net Income

$5.16B

25.7% Net Margin

EPS (Diluted)

$6.70

Total Assets

$69.01B

Cash & Equivalents

$3.73B

Free Cash Flow

$8.23B

Financial Statements
Beta
Revenue$20.06B
Cost of Revenue$4.42B
Gross Profit$15.64B
SG&A Expenses$4.70B
Operating Expenses$13.87B
Operating Income$6.19B
Interest Expense$1.07B
Net Income$5.16B
EPS (Basic)$6.80
EPS (Diluted)$6.70
Shares Outstanding (Basic)759.00M
Shares Outstanding (Diluted)770.00M

Key Highlights

  • 1Total revenues increased by 7% to $20.06 billion in 2014, driven by a 6% rise in total product sales.
  • 2Product sales in the Rest of World (ROW) grew by 11%, outpacing the 5% growth in U.S. product sales.
  • 3Significant pipeline progress includes regulatory submissions and positive Phase 3 data for Repatha™ (evolocumab) and FDA accelerated approval for BLINCYTO™ (blinatumomab).
  • 4Amgen initiated a restructuring plan involving staff reductions and facility consolidations, expected to result in significant pre-tax charges but aimed at improving cost structure and reinvesting in innovation.
  • 5The company continued to return capital to shareholders with a 30% increase in quarterly dividends and active stock repurchases.
  • 6Key products like XGEVA® and Prolia® demonstrated strong double-digit growth (20% and 38% respectively).
  • 7Amgen is expanding its biosimilar development program, planning to add three more biosimilar molecules to its portfolio, bringing the total to nine.

Frequently Asked Questions

Amgen's product sales growth in 2014 was driven by several factors. Strong performance from key products like XGEVA® (20% growth) and Prolia® (38% growth) contributed significantly. The inclusion of a full year of Kyprolis® sales following the Onyx acquisition in late 2013 also boosted overall product sales. International sales showed robust growth of 11%, indicating successful global expansion efforts.

The filing highlights several critical pipeline advancements. Repatha™ (evolocumab) for high cholesterol advanced with submissions to the EMA and FDA, which accepted it for review. BLINCYTO™ received FDA accelerated approval for Philadelphia chromosome-negative relapsed or refractory B-cell precursor ALL in December 2014. Other promising candidates include Corlanor® (ivabradine) for chronic heart failure, brodalumab for inflammatory diseases, and AMG 416 for secondary hyperparathyroidism, all showing progress in late-stage trials or regulatory submissions.

Amgen announced a significant restructuring plan in the second half of 2014, involving staff reductions and facility closures. This plan is designed to improve the company's cost structure and reallocate resources towards key growth opportunities, including advancing its innovative pipeline, preparing for new product launches, and expanding its biosimilars portfolio. The company is also investing in 'Next-Generation Biomanufacturing' facilities to enhance productivity and reduce costs.

Amgen faces several key risks and challenges. Increasing competition from biosimilars and generic products is a major concern, particularly as patents for key products like Neulasta® and EPOGEN® approach expiration. Regulatory hurdles and the lengthy, costly process of drug development and approval remain significant challenges. Additionally, pricing pressures and reimbursement challenges from third-party payers, both governmental and private, could impact sales and profitability. The company also highlights risks related to manufacturing disruptions, supply chain dependencies, and ongoing litigation.